Non-Hodgkin Lymphoma Diagnostics Market: Global Market Estimation, Dynamics, Trends, Competitor Analysis 2016-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Non-Hodgkin Lymphoma Diagnostics Market By Test Type (Physical examination, Biopsy, Cell and tissue study, Blood tests, Imaging tests, and Lumbar puncture), By Lymphoma Type (Aggressive lymphomas and Indolent lymphomas), By End User (Hospitals, Diagnostic centers and Research laboratories) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

The non-hodgkin lymphoma diagnostics market is valued at USD billion in 2021 and is poised to grow at a significant CAGR over 2022–2028. Several factors, such as AIDS infection, immunosuppressive medications, occupational exposures, pesticide proximity, and smoking, are key risk factors for the development of NHL. With around 4% of all cancer cases in the US, non-Hodgkin lymphoma (NHL) is one of the most prevalent tumours. According to the American Cancer Society, there will be an estimated, NHL will be identified in about 80,470 persons (44,120 men and 36,350 women). Adults and children are both included in this. Non-Hodgkin lymphoma is the second most frequent cancer in people with HIV, and some people with AIDS also have lymphoma. It is true that non-Hodgkin lymphoma patients should routinely undergo HIV and hepatitis virus screenings. A thorough assessment of the burden brought on by malignancies was made by the Global Burden of Disease study (GBDs), which made it easier to monitor the temporal patterns in the disease burden. The idea that there is a connection between obesity and NHL has been supported by concurrent rises in the prevalence of obesity and the incidence of NHL during the past few decades. The prognosis for those who have non-lymphoma Hodgkin’s has improved as a result of improvements in diagnosis and therapy. Researchers are investigating ways to avoid infections such HHV-8, HIV, HTLV-1, and H. pylori that have been linked to non-Hodgkin lymphoma. The chance of getting non-Hodgkin lymphoma may be decreased by avoiding exposure to certain substances, such as lead, arsenic, pesticides, vinyl chloride, and asbestos.

Recent Market Developments:

In May 2021, PerkinElmer, Inc. purchased Immunodiagnostic Systems Holdings PLC in order to grow its overall diagnostics business for about $155 million.

Non-Hodgkin Lymphoma Diagnostics Market

MARKET SUMMARY
-
x
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR–X%
  • Largest Market– North America

Non-Hodgkin Lymphoma Diagnostics Market

  • The global non-hodgkin lymphoma diagnostics market report gives comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The non-hodgkin lymphoma diagnostics market report gives historical, current, and future market sizes (US$ Mn) based on test type, lymphoma type, end-user and geography.
Key Players
  • BioGenex
  • BIO-RAD LABORATORIES Inc
  • BIOCEPT, INC.
  • ILLUMINA, INC.
  • MYRIAD GENETICS, INC.
  • QIAGEN N.V.
  • bioMeriux SA (France)
Non-Hodgkin Lymphoma Diagnostics Market Drivers

Non-Hodgkin lymphoma (NHL) is a type of malignant lymphoid malignancies that preferentially involve nodes and have unique histological and/or biological properties. A frequent haematological malignancy is non-Hodgkin lymphoma (NHL). NHL incidence rates for men and women in India, adjusted for age, are 2.9/100,000 and 1.5/100,000, respectively. These incidence rates represent around one-fourth of those from North America or Western Europe. In India, the incidence of cancer is many times greater in urban than in rural areas, with the incidence being higher in metropolitan areas and among Indian immigrants, suggesting that urban lifestyles and economic development may raise the prevalence of cancer.


Asia-Pacific Got Significant Share

Non-Hodgkin Lymphoma Diagnostics Market

The Non-Hodgkin Lymphoma Diagnostics market in Asia Pacific is likely to hold a significant revenue share in 2021, and, in the following years, it is predicted to increase rapidly. The growth is due to increasing NHL prevalence along with the region's access to healthcare facilities. Increased propensity for urban lifestyles and rapid economic development are to blame for the rise in sickness cases in the area. Multiple prospects for industrial advancement will be further infused by the availability of subpar diagnostic facilities. North America held considerable market share during the estimated period. The region's high prevalence of Non-Hodgkin lymphoma (NHL) and access to cutting-edge therapies are serving as the market's primary growth factors.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analys
Non-Hodgkin Lymphoma Diagnostics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The non-hodgkin lymphoma diagnostics market is projected to expand at a CAGR of x% during the forecast period.

BD, Aspire Medical Innovation, Thermo Fisher Scientific, Medtronic, Merit Medical Systems

Asia Pacific is the fastest-growing region for non-hodgkin lymphoma diagnostics market


Report

Table Of Content


Report

Company Profile

  • BD
  • Aspire Medical Innovation
  • Thermo Fisher Scientific
  • Medtronic
  • Merit Medical Systems
  • Argon Medical
  • Depuy Synthes (Johnson & Johnson)
  • Merck KGaA
  • Medplus Inc.
  • LSL HEALTHCARE, INC.
  • Agilent Technologies, Inc.
  • Cardinal Health
  • Abbott Laboratories
  • PerkinElmer, Inc. (PerkinElmer)

Description

The non-hodgkin lymphoma diagnostics market is valued at USD billion in 2021 and is poised to grow at a significant CAGR over 2022–2028. Several factors, such as AIDS infection, immunosuppressive medications, occupational exposures, pesticide proximity, and smoking, are key risk factors for the development of NHL. With around 4% of all cancer cases in the US, non-Hodgkin lymphoma (NHL) is one of the most prevalent tumours. According to the American Cancer Society, there will be an estimated, NHL will be identified in about 80,470 persons (44,120 men and 36,350 women). Adults and children are both included in this. Non-Hodgkin lymphoma is the second most frequent cancer in people with HIV, and some people with AIDS also have lymphoma. It is true that non-Hodgkin lymphoma patients should routinely undergo HIV and hepatitis virus screenings. A thorough assessment of the burden brought on by malignancies was made by the Global Burden of Disease study (GBDs), which made it easier to monitor the temporal patterns in the disease burden. The idea that there is a connection between obesity and NHL has been supported by concurrent rises in the prevalence of obesity and the incidence of NHL during the past few decades. The prognosis for those who have non-lymphoma Hodgkin’s has improved as a result of improvements in diagnosis and therapy. Researchers are investigating ways to avoid infections such HHV-8, HIV, HTLV-1, and H. pylori that have been linked to non-Hodgkin lymphoma. The chance of getting non-Hodgkin lymphoma may be decreased by avoiding exposure to certain substances, such as lead, arsenic, pesticides, vinyl chloride, and asbestos.

Recent Market Developments:

In May 2021, PerkinElmer, Inc. purchased Immunodiagnostic Systems Holdings PLC in order to grow its overall diagnostics business for about $155 million.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX